Hospitales Universitarios Virgen Macarena y Virgen del Rocío

Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study (2019) Peichl P, Alten R, Galeazzi M, Lorenz HM, Nüsslein H, Navarro F, Elbez Y, et al. Journal article Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) (+) ribociclib (RIB) (2019) Slamon DJ, Neven P, Chia S, Fasching P, De Laurentiis M, Im SA, Petrakova K, et al. Conference contribution Consensus statements and recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 11-13 November 2018 (2019) Ahmed N, Audebert H, Turc G, Cordonnier C, Christensen H, Sacco S, Sandset EC, et al. Journal article Correction to: Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study (Clinical Rheumatology, (2019), 38, 5, (1413-1424), 10.1007/s10067-019-04449-w) (2019) Alten R, Mariette X, Lorenz HM, Nüsslein H, Galeazzi M, Navarro F, Chartier M, et al. Journal article, Erratum Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study (2019) Alten R, Mariette X, Lorenz HM, Nüsslein H, Galeazzi M, Navarro F, Chartier M, et al. Journal article Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3 (2018) Slamon DJ, Neven P, Chia S, Fasching P, De Laurentiis M, Im SA, Petrakova K, et al. Journal article Safety and Performance of the Resorbable Magnesium Scaffold, Magmaris in a Real World Setting - First 400 Subjects at 12-month Follow-up of the BIOSOLVE-IV Registry (2018) Lee M, Wlodarczak A, Bennett J, Torzewski J, Haude M, Vrolix M, Buck T, et al. Conference contribution Telotristat Ethyl in Carcinoid Syndrome: Safety and Efficacy Results of an Open-Label Extension of the TELECAST Phase 3 Clinical Trial (2018) Pavel M, Benavent M, Perros P, Srirajaskanthan R, Warner RRP, Kulke MH, Anthony LB, et al. Conference contribution The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24-25, 2015. Workshop Report (2016) Kager L, Whelan J, Dirksen U, Hassan B, Anninga J, Bennister L, Bovee JVMG, et al. Journal article Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis (2015) Ochoa E, Martin JE, Assassi S, Beretta L, Carreira P, Guillen A, Simeon CP, et al. Journal article